Jeremie Calais, MD, MSc, presented “PSMA PET Imaging in Advanced Prostate Cancer” virtually during the Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 15th, 2020.
How to cite: Calais, Jeremie. “PSMA PET Imaging in Advanced Prostate Cancer” October 15th, 2020. Accessed Nov 2024. https://grandroundsinurology.com/psma-pet-imaging-in-advanced-prostate-cancer/
Summary:
Jeremie Calais, MD, MSc, Assistant Professor and Director of the Clinical Research Program of the Ahmanson Translational Theranostics Division at UCLA, discusses the use of prostate-specific membrane antigen PET imaging, or PSMA PET, in diagnosing advanced prostate cancer. Noting that PSMA PET is currently the most sensitive imaging technique, he reviews well-known studies, STOMP and ORIOLE, and shares patient success stories of PSMA PET guided therapy. PSMA PET is able to detect tumor deposits of 4.5 mm with 90% accuracy and 2.3 mm with 50% accuracy making it more effective in locating disease migration. However, there will still be some micrometastases that are too small to yet be detected by PSMA PET. Because active distant lesions are not successfully identified under all imaging types, Dr. Calais proposes including the modality employed when stating a patient’s disease progression; for example, “mCRPC by PSMA-PET,” thereby expressing the means by which the disease stage was determined. PSMA PET can be used to follow disease mutation and more quickly identify non-metastatic castration-resistant prostate cancer.
For more on recent advances in this topic, please see this interview with Robert E. Reiter, MD, on the recent FDA approval of PSMA PET for prostate cancer.
The Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer brings together key international opinion leaders of every clinical subspecialty involved in patient care. This event is an integral part of the AdMeTech Foundation’s Annual Summit, which was established in 2016 and become seminal in shaping the state of the art and future vision for precision care. The goal of this event is three-fold: 1) Educating the key stakeholders; 2) Supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and 3) Expediting clinical adoption of promising novel diagnostics and therapeutics.
ABOUT THE AUTHOR
Dr Jérémie Calais, MD, PhD, is an Associate Professor of Nuclear Medicine and Theranostics in the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA). He is the director of the UCLA Theranostics Program and the Director of the Clinical Research Program of the Ahmanson Translational Theranostics Division. Dr. Calais earned his medical degree and Master of Science degree at the University of Paris in France.
Dr. Calais is a nuclear medicine physician specializing in cancer imaging and theranostics. He conducts investigator-initiated and industry-sponsored clinical trials of targeted molecular imaging and therapy. His goal is to improve the outcome of patients with cancer through theranostic approaches and the application of knowledge gained from preclinical models and clinical studies.
